Recognized as a “Rising Star” by IFLR1000, the Legal 500 Asia Pacific and China Law & Practice Awards, Amy Liu is Counsel in Simpson Thacher’s Corporate Department, where she focuses on mergers and acquisitions and private equity. She has advised corporate clients and private equity sponsors in connection with a variety of public and private merger and acquisition transactions, leveraged buyouts, minority and strategic investments, and other corporate matters across a broad range of industries.
Read Full Biography...
Work Highlights
- Blackstone Capital Partners, KKR Asia, Primavera Capital and Warburg Pincus in various private equity investments and acquisitions in Greater China
- Alibaba Group and Ant Group in various strategic investments
- Primavera Capital Acquisition Corporation in its US$1.9 billion de-SPAC transaction with Lanvin Group
- Buyer consortium in the US$1.58 billion going-private transaction for New Frontier Health
- New Frontier Corporation in its US$1.3 billion acquisition of United Family Healthcare
- Ant Group in its Series C equity financing totaling US$14 billion
- Alibaba Group in its strategic new retail partnership with Starbucks in China
- China National Chemical Corporation in its acquisition of Syngenta AG for approximately US$43 billion
Accolades
-
“Rising Star,” The Legal 500 Asia Pacific 2023
-
“Rising Star,” IFLR1000 2023
-
“Rising Star of the Year,” China Law & Practice Awards 2019
Education
-
Harvard Law School, 2014 J.D.
-
Grinnell College, 2011 B.A.
Languages Spoken
-
English
-
Mandarin
-
Cantonese
Recognized as a “Rising Star” by IFLR1000, the Legal 500 Asia Pacific and China Law & Practice Awards, Amy Liu is Counsel in the Firm’s Corporate Department, focusing on mergers and acquisitions and private equity. She has advised corporate clients and private equity funds in connection with a variety of public and private merger and acquisition transactions, leveraged buyouts, minority and strategic investments, and other corporate matters across a broad range of industries.
Amy’s recent representative matters include advising:
- Blackstone Capital Partners, KKR Asia, Primavera Capital and Warburg Pincus in various private equity investments and acquisitions in Greater China
- Alibaba Group and Ant Group in various strategic investments
- Primavera Capital Acquisition Corporation in its US$1.9 billion de-SPAC transaction with Lanvin Group
- Buyer consortium in the US$1.58 billion going-private transaction for New Frontier Health
- New Frontier Corporation in its US$1.3 billion acquisition of United Family Healthcare
- Ant Group in its Series C equity financing totaling US$14 billion
- Alibaba Group in its strategic new retail partnership with Starbucks in China
- China National Chemical Corporation in its acquisition of Syngenta AG for approximately US$43 billion
Amy received her J.D. from Harvard Law School in 2014 and her B.A. in Classics, with honors, from Grinnell College in 2011. She speaks English, Mandarin and Cantonese.